{
    "nct_id": "NCT05382286",
    "official_title": "A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1",
    "inclusion_criteria": "* Individuals with locally advanced, inoperable, or metastatic triple-negative breast cancer (TNBC) who have not received previous systemic therapy for advanced disease and whose tumors are programmed cell death ligand 1 (PD-L1) positive at screening.\n\n  * Individuals must have completed treatment for Stage I to III breast cancer, if indicated, and â‰¥ 6 months must have elapsed between completion of treatment with curative intent and first documented local or distant disease recurrence.\n  * Individuals presenting with de novo metastatic TNBC are eligible for this study.\n  * TNBC status and tumor PD-L1 combined positive score (CPS) will be confirmed centrally on a recent or archival tumor specimen.\n  * Individuals must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria as evaluated locally.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n* Demonstrates adequate organ function\n* Male and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.\n* Individuals with HIV must be on antiretroviral therapy (ART) and have a well-controlled HIV infection/disease.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Positive serum pregnancy test or women who are lactating.\n* Received prior therapy with an agent directed to another stimulatory or coinhibitory T-cell receptor.\n* Individuals may not have received systemic anticancer treatment (with the exception of endocrine therapy) within the previous 6 months or radiation therapy within 2 weeks prior to enrollment.\n* Individuals may not be participating in a study with an investigational agent or investigational device within 4 weeks prior to randomization. Individuals participating in observational studies are eligible.\n* Have previously received topoisomerase 1 inhibitors or antibody drug conjugates containing a topoisomerase inhibitor.\n* Have an active second malignancy.\n* Have active serious infection requiring antibiotics.\n* Individuals positive for HIV-1 or 2 with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.\n* Have active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.\n* Has an active autoimmune disease that has required systemic treatment in the past 2 years.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}